Compare Merck & Co., Inc. (MRK) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Sea Limited — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Sea Limited trades at $107.85 (market cap $69.41B). The key difference: Merck & Co., Inc. is far larger — about 5.3× Sea Limited's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| MRK | SE | |
|---|---|---|
Market Cap | $366.28B | $69.41B |
Sector | Health | Media |
52-Week High | $156.43 | $196.50 |
52-Week Low | $77.60 | $78.16 |
Enterprise Value | $413.04B | $64.44B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
SE trades at $113.33, up 1.11% today, with a bullish technical outlook as the price sits above key support at $111. Revenue grew to $22.94B in 2025, with net income reaching $1.58B, and analysts project a consensus price target of $143.67. Recent insider sales by executives have occurred, but the company maintains strong cash flow from operations of $5.02B.
The outlook is positive given robust revenue growth and improving profitability, but risks include competitive pressures in e-commerce and potential volatility from insider selling. Wall Street sentiment remains bullish with 70% buy ratings, supporting upside potential if earnings continue to beat expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
